Hong Kong Journal of Nephrology
Volume 12, Issue 1 , Pages 2-5 , April 2010

Diabetic Kidney Disease: Act Now or Pay Later

  • Robert C. Atkins
    • ,
  • Paul Zimmet
    • ,
  • For the 2010 International Society of Nephrology/International Federation of Kidney Foundations World Kidney Day Steering Committee (RA) and the International Diabetes Federation (PZ)

      Affiliations

    • ISN/IFKF 2010 World Kidney Day Steering Committee: William G. Couser, MD, Miguel Riella, MD, co-chairpersons. Georgi Abraham, MD, Paul Beerkens, John Feehally, MD, Guillermo Garcia-Garcia, MD, Dan Larson, Philip K.T. Li, MD, Bernardo Rodriguez-Iturbe, MD. E-mail: Marie-Agnes.Cederborg@interel.eu

References 

  1. International Diabetes Federation and International Society of Nephrology  . Diabetes and Kidney Disease: Time to Act . Brussels: IDF & ISN; 2003;
  2. Zimmet P , Alberti K , Shaw J . Global and societal implications of the diabetes epidemic . Nature . 2001;414:782–787
  3. King H , Aubert R , Herman W . Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections . Diabetes Care . 1998;21:1414–1431
  4. Yoon KH , Lee JH , Kim JW , Cho JH , Choi YH , Ko SH , et al.   Epidemic obesity and type 2 diabetes in Asia . Lancet . 2006;368:1681–1688
  5. Sicree R , Shaw J , Zimmet P . Diabetes and impaired glucose tolerance . In:  Gan D editors. Diabetes Atlas . 3rd edition. Brussels: International Diabetes Federation; 2006;p. 15–109
  6. Reutens AT , Prentice L , Atkins R . The epidemiology of diabetic kidney disease . In:  Ekoé JM ,  Rewers M ,  Williams R editor. The Epidemiology of Diabetes Mellitus: An International Perspective . 2nd edition. Chichester: John Wiley & Sons; 2008;p. 499–518
  7. National Institutes of Health  , National Institute of Diabetes and Digestive and Kidney Diseases  . International comparisons . In: Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States . Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2007;p. 239–254 2007
  8. Appendix II . In:  McDonald S ,  Excell L ,  Livingston B editor. ANZDATA Registry Report 2008 . Adelaide, Australia: Australia and New Zealand Dialysis and Transplant Registry; 2008;p. 1–97
  9. Yamagata K , Iseki K , Nitta K , Imai H , Iino Y , Matsuo S , et al.   Chronic kidney disease perspectives in Japan and the importance of urinalysis screening . Clin Exp Nephrol . 2008;12:1–8
  10. Lysaght M . Maintenance dialysis population dynamics: current trends and long-term implications . J Am Soc Nephrol . 2002;13(Suppl 1):S37–S40
  11. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64) . Kidney Int . 2003;63:225–232
  12. Retnakaran R , Cull CA , Thorne KI , Adler AI , Holman RR , UKPDS Study Group  . Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74 . Diabetes . 2006;55:1832–1839
  13. Parving HH , Lewis JB , Ravid M , Remuzzi G , Hunsicker LG , DEMAND Investigators  . Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective . Kidney Int . 2006;69:2057–2063
  14. Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, et al  Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes . J Am Soc Nephrol . 2009;20:1813–1821
  15. Dunstan DW , Zimmet PZ , Welborn TA , De Courten MP , Cameron AJ , Sicree RA , et al.   The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study . Diabetes Care . 2002;25:829–834
  16. White SL , Polkinghorne KR , Cass A , Shaw J , Atkins RC , Chadban SJ . Limited knowledge of kidney disease in a survey of AusDiab study participants . Med J Aust . 2008;188:204–208
  17. Whaley-Connell A, Sowers JR, McCullough PA, Roberts T, McFarlane SI, Chen SC, et al  Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) . Am J Kidney Dis . 2009;53(4 Suppl 4):S11–S21
  18. Thomas MC , Viberti G , Groop PH . Screening for chronic kidney disease in patients with diabetes: are we missing the point? . Nat Clin Pract Nephrol . 2008;4:2–3
  19. Holman RR , Paul SK , Bethel MA , Matthews DR , Neil HA . 10-year follow-up of intensive glucose control in type 2 diabetes . N Engl J Med . 2008;359:1577–1589
  20. Bilous R . Microvascular disease: what does the UKPDS tell us about diabetic nephropathy? . Diabet Med . 2008;25(Suppl 2):25–29
  21. Gaede P , Lund-Andersen H , Parving HH , Pedersen O . Effect of a multifactorial intervention on mortality in type 2 diabetes . N Engl J Med . 2008;358:580–591
  22. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, et al  Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial . Lancet . 2007;370:829–840
  23. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al  Intensive blood glucose P ontrol and vascular outcomes in patients with type 2 diabetes . N Engl J Med . 2008;358:2560–2572
  24. Zoungas S, de Galan BE, Ninomiya T, Grobbee D, Hamet P, Heller S, et al  Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial . Diabetes Care . 2009;32:2068–2074
  25. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al  Preventing microalbuminuria in type 2 diabetes . N Engl J Med . 2004;351:1941–1951
  26. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes . N Engl J Med . 2001;345:870–878
  27. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes . N Engl J Med . 2001;345:851–860
  28. Burney B , Kalaitzidis R , Bakris G . Novel therapies of diabetic nephropathy . Curr Opin Nephrol Hypertens . 2009;18:107–111

PII: S1561-5413(10)60002-6

doi: 10.1016/S1561-5413(10)60002-6

Hong Kong Journal of Nephrology
Volume 12, Issue 1 , Pages 2-5 , April 2010

Article Tools